keyword
MENU ▼
Read by QxMD icon Read
search

Farxiga

keyword
https://www.readbyqxmd.com/read/27677067/farxiga-and-fetzima-mix-ups
#1
Ann Shastay
No abstract text is available yet for this article.
October 2016: Home Healthcare Now
https://www.readbyqxmd.com/read/26131942/dapagliflozin-farxiga-for-type-2-diabetes-mellitus
#2
Clinton K Pong, George E Maxted
No abstract text is available yet for this article.
June 15, 2015: American Family Physician
https://www.readbyqxmd.com/read/25694411/dapagliflozin-a-new-sodium-glucose-cotransporter-2-inhibitor-for-treatment-of-type-2-diabetes
#3
REVIEW
Eva M Vivian
PURPOSE: The pharmacologic properties and clinical efficacy of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, are reviewed. SUMMARY: Dapagliflozin (Farxiga, AstraZeneca) is a selective SGLT2 inhibitor approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Dapagliflozin lowers blood glucose independent of insulin secretion and action by inhibiting renal reabsorption of glucose, thus promoting increased urinary excretion of glucose...
March 1, 2015: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/25671589/selective-reaction-monitoring-of-negative-electrospray-ionization-acetate-adduct-ions-for-the-bioanalysis-of-dapagliflozin-in-clinical-studies
#4
Qin C Ji, Xiaohui Xu, Eric Ma, Jane Liu, Shenita Basdeo, Guowen Liu, William Mylott, David W Boulton, Jim X Shen, Bruce Stouffer, Anne-Françoise Aubry, Mark E Arnold
Dapagliflozin (Farxiga), alone, or in the fixed dose combination with metformin (Xigduo), is an orally active, highly selective, reversible inhibitor of sodium-glucose cotransporter type 2 (SGLT2) that is marketed in United States, Europe, and many other countries for the treatment of type 2 diabetes mellitus. Here we report a liquid chromatography-tandem mass spectrometry (LC-MS/MS) bioanalytical assay of dapagliflozin in human plasma. A lower limit of quantitation (LLOQ) at 0.2 ng/mL with 50 μL of plasma was obtained, which reflects a 5-fold improvement of the overall assay sensitivity in comparison to the previous most sensitive assay using the same mass spectrometry instrumentation...
March 17, 2015: Analytical Chemistry
https://www.readbyqxmd.com/read/25609661/dapagliflozin-a-sodium-glucose-cotransporter-2-inhibitor-for-the-treatment-of-diabetes-mellitus
#5
Portia N Davis, Uche Anadu Ndefo, Ashley Oliver
OBJECTIVE: To review clinical evidence for the efficacy, safety, and tolerability of dapagliflozin (Farxiga-AstraZeneca), a sodium glucose cotransporter 2 inhibitor, as monotherapy or in combination with other hypoglycemic agents for the treatment of type 2 diabetes. DATA SOURCES: Literature was identified through a systematic MEDLINE search of clinical trial results for dapagliflozin. DATA SYNTHESIS: Multiple controlled clinical trials have established the efficacy, safety, and tolerability of dapagliflozin as monotherapy or in combination with other therapies for type 2 diabetes...
April 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/25418019/pharmacokinetics-pharmacodynamics-and-clinical-efficacy-of-dapagliflozin-for-the-treatment-of-type-2-diabetes
#6
REVIEW
Marianna Maranghi, Anna Carnovale, Cosimo Durante, Giovanna Tarquini, Giusy Tiseo, Sebastiano Filetti
INTRODUCTION: Dapagliflozin (DAPA) (Farxiga or Forxiga) is a sodium glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes mellitus(T2DM) treatment. AREAS COVERED: The review focuses on the pharmacokinetics (PK), pharmacodynamics(PD) and clinical studies published on DAPA. The authors searched PubMed database for English language studies describing DAPA characteristics and use in T2DM subjects published through June 2014. EXPERT OPINION: DAPA exhibits favorable PK and PD properties and is effective in reducing glycemic levels...
January 2015: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/25389049/dapagliflozin-a-review-of-its-use-in-patients-with-type-2-diabetes
#7
REVIEW
Greg L Plosker
Dapagliflozin (Forxiga(®), Farxiga(®)) is an orally administered sodium-glucose co-transporter-2 (SGLT2) inhibitor used in the management of patients with type 2 diabetes. Dapagliflozin reduces renal glucose reabsorption by inhibiting the transporter protein SGLT2 in the renal proximal tubule, thereby increasing urinary glucose excretion and reducing blood glucose levels. Its mechanism of action is independent of insulin secretion or action; therefore, dapagliflozin provides complementary therapy when used in combination with other antihyperglycaemic drugs...
December 2014: Drugs
https://www.readbyqxmd.com/read/24951310/dapagliflozin-for-the-treatment-of-type-2-diabetes-mellitus
#8
REVIEW
Andrew Aylsworth, Zachary Dean, Cody VanNorman, Arinze Nkemdirim Okere
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trials, and adverse effects of dapagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor. DATA SOURCES: Data were gathered from articles indexed in PubMed, International Pharmaceutical from (2006 to April 2014) was performed using the following terms "dapagliflozin," "SGLT-2 inhibitor," and "Farxiga." Abstracts and manufacturer's package insert were also used as an additional reference. STUDY SELECTION AND DATA EXTRACTION: All English language prospective randomized, double-blinded trials evaluating the efficacy of dapagliflozin for the treatment of type 2 diabetes were identified...
September 2014: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/24790394/pharmaceutical-approval-update
#9
Marvin M Goldenberg
Dapaglifozin (Farxiga) for improved glycemic control in type-2 diabetes, and trametinib (Mekinist) in combination with dabrafenib (Tafinlar) for the treatment of advanced, unresectable melanoma.
March 2014: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/24663030/dapagliflozine-farxiga-for-type-2-diabetes
#10
(no author information available yet)
No abstract text is available yet for this article.
February 17, 2014: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/24566458/dapagliflozine-farxiga-for-type-2-diabetes
#11
(no author information available yet)
No abstract text is available yet for this article.
February 17, 2014: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"